Skip to content

Observation on the clinical efficacy of Bushenziyinguchongkeli in the treatment of excessive menstruation

Observation on the clinical efficacy of Bushen Ziyin Guchong keli in the treatment of excessive menstruation

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2025001707
Enrollment
Unknown
Registered
2025-09-11
Start date
2025-05-31
Completion date
Unknown
Last updated
2025-10-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

menorrhagia

Interventions

Experimental group:Give Bushenziyinguchongtang twice a day.Start taking the medicine on the 2nd day of menstruation and continue to take the medicine for 7 days after the bleeding stops
3 menstrual cycles of the medicine shall be regarded as one course of treatment and one course of the medicine shall be administered.
Control group:Drospirenone and Ethinyl Estradiol Tablets (II) (Yusuyue), begin on the 3rd day of menstruation. Take 1 tablet once daily by mouth for 24 consecutive days (24 red tablets). One treatment

Sponsors

Maternal and Child Health Hospital of Hubei Province
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 55 Years

Inclusion criteria

Inclusion criteria: (1) Comply with the Chinese and Western medical diagnostic criteria for excessive menstruation; (2) Compliance with the Chinese medicine diagnostic type of kidney yin deficiency; (3) Patients aged 18-55 years old; (4) Patients who have not used any hormone therapy in the last 3 months; (5) Voluntarily signed the informed consent form; (6) Cooperating with the treatment and meeting the follow-up requirements

Exclusion criteria

Exclusion criteria: (1) Patients with serious primary diseases such as cardiovascular cerebrovascular hepatic renal and haematopoietic systems and mental diseases; (2) Patients with other primary endocrine diseases (hyperthyroidism hypothyroidism etc.) that can cause menstrual disorders and gynecological bleeding disorders caused by organic lesions; (3) Patients who may not be able to complete the whole study; (4) Those who have unstable working environment etc. which may lead to loss of visits.

Design outcomes

Primary

MeasureTime frame
Measurement of menstrual blood volume;Complete Coagulation Panel;Complete Blood Count;Complete Endocrine Panel;Five Thyroid Function Tests;VEGF;ANG;Endometrial thickness;

Secondary

MeasureTime frame
Clinical Traditional Chinese Medicine Symptoms;Clinical Single Symptom Score;

Countries

China

Contacts

Public ContactXiaotao Huang

Maternal and Child Health Hospital of Hubei Province

huang68xt@sina.com18963952898

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026